Evidence for a Common Binding Cavity for Three General Anesthetics within the GABA_A Receptor

Andrew Jenkins,1 Eric P. Greenblatt,2 Howard J. Faulkner,3 Edward Bertaccini,4 Adam Light,5 Audrey Lin,5 Alyson Andreasen,1 Anna Viner,3 James R. Trudell,4 and Neil L. Harrison1

1C. V. Starr Laboratory for Molecular Neuropharmacology, Department of Anesthesiology, Weill Medical College of Cornell University, New York, New York 10021, 2Department of Anesthesia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, 3Imperial College School of Medicine, London SW7 2AZ, United Kingdom, 4Department of Anesthesia, Stanford University School of Medicine, Stanford, California 94305, and 5The University of Chicago, Chicago, Illinois 60637

The GABA_A receptor is an important target for a variety of general anesthetics (Franks and Lieb, 1994) and for benzodiazepines such as diazepam. Specific point mutations in the GABA_A receptor selectively abolish regulation by benzodiazepines (Rudolph et al., 1999; McKernan et al., 2000) and by anesthetic ethers (Mihic et al., 1997; Krasowski et al., 1998; Koltchine et al., 1999), suggesting the existence of discrete binding sites on the GABA_A receptor for these drugs. Using anesthetics of different molecular size (isoflurane > halothane > chloroform) together with complementary mutagenesis of specific amino acid side chains, we estimate the volume of a proposed anesthetic binding site as between 250 and 370 Å³. The results of the “cutoff” analysis suggest a common site of action for the anesthetics isoflurane, halothane, and chloroform on the GABA_A receptor. Moreover, the data support a crucial role for Leu232, Ser270, and Ala291 in the α subunit in defining the boundaries of an amphipathic cavity, which can accommodate a variety of small general anesthetic molecules.

Key words: anesthetic; GABA; binding site; allosteric; receptor; molecular volume

Many general anesthetics with simple chemical structures prolong the duration of synaptic inhibition via allosteric regulation of GABA_A receptors (Jones and Harrison, 1993; Nishikawa and MacIver, 2000). Reciprocal synaptic connections between cortical interneurons can generate high-frequency (30–60 Hz) oscillatory activity (Jefferys et al., 1996), and entrainment of these local inhibitory microcircuits results in synchronization of these “gamma oscillations” (Whittington et al., 1995). Such high-frequency activity has been linked to cognitive functions such as selective attention (Bragin et al., 1997), and reductions in the characteristic frequency of these oscillations, so that drugs that prolong the time course of synaptic inhibition also decrease the characteristic frequency of these oscillations (Rampil, 1998). GABAAergic inhibition plays a fundamental role in the timing of these high-frequency oscillations, so that drugs that prolong the time course of synaptic inhibition also decrease the characteristic frequency of these oscillations (Whittington et al., 1996), eventually imposing slow, high-amplitude waves in both the EEG and in vitro model systems. Decreases in the EEG spectral edge frequency accompany decrements in cognitive function during the induction of anesthesia (Rampil, 1998). GABA_A receptors therefore represent one of the major neurobiological substrates for the action of general anesthetics, especially with regard to the ability of these drugs to induce hypnosis and loss of consciousness (Franks and Lieb, 1994).

Inhaled anesthetics alter the function of GABA_A receptors in acutely dissociated neurons (Nakahiro et al., 1989; Wakamori et al., 1991; Li and Pearce, 2000) and in heterologous expression systems (Harrison et al., 1993; Mihic et al., 1997; Jenkins et al., 1999). The modulatory action of these inhaled agents, unlike that of diazepam, is independent of the γ subunit of the GABA_A receptor (Harrison et al., 1993; Krasowski et al., 1998; Koltchine et al., 1999). In this study, we have therefore examined the action of these anesthetics on GABA_A receptors consisting only of α and β subunits. GABA_A receptor modulation by the anesthetic ether isoflurane is abolished by a point mutation at S270 in the TM2 segment of the α subunit (Mihic et al., 1997; Krasowski et al., 1998), whereas the effects of diazepam and other sedative-hypnotic benzodiazepines are abolished by mutating H101 to arginine in the large extracellular N-terminal domain of the α subunit (Rudolph et al., 1999; McKernan et al., 2000). However, although it is known that flunitrazepam binds to H101 but not R101 (Duncalf et al., 1996), it is not known why S270 permits receptor modulation by isoflurane, whereas an isoleucine residue at this position does not. The present study probes the involvement of S270 and of two other residues in greater detail and extends our analysis of anesthetic action to include the alkanes halothane and chloroform.

This article is published in The Journal of Neuroscience, Rapid Communications Section, which publishes brief, peer-reviewed papers online, not in print. Rapid Communications are posted online approximately one month earlier than they would appear if printed. They are listed in the Table of Contents of the next open issue of JNeurosci. Cite this article as: JNeurosci, 2001, 21:RC136 (1–4). The publication date is the date of posting online at www.jneurosci.org.
MATERIALS AND METHODS

Site-directed mutagenesis and electrophysiology. To create the mutant series at GABA_α receptors, α2 Ser270 mutations were introduced into the cDNA encoding the human GABA_α receptor α2 subunit at bases 890 to 892, with simultaneous loss of a Ddel restriction site (Koltchine et al., 1999). Additional mutations were created at Ala291 and Leu232 using either the Unique Site Elimination method (Amersham Pharmacia Biotech, Arlington Heights, IL) or a Pfu polymerase/DpnI selection method (QuickChange; Stratagene, La Jolla, CA). The sequences of all cDNA inserts were confirmed throughout by double-stranded sequencing. Human embryonic kidney (HEK) 293 cells were maintained in culture on glass coverslips and transfected with cDNAs encoding wild-type or mutant α2 subunits and wild-type β1 subunits. Recordings were made using the whole-cell patch-clamp technique as described previously (Koltchine et al., 1999). All drugs and solutions were applied rapidly to the cell by local perfusion using a motor-driven solution exchange device; recordings were made at room temperature (20–22°C). Bath concentrations of the anesthetics were measured using gas chromatography and represent 90–95% of the total applied drug concentration. Numerical data are presented throughout as mean ± SE. Concentration–response curves were determined for the wild-type and each mutant GABA_α receptor (Koltchine et al., 1999). Potentiation of a submaximal GABA response by each anesthetic was then calculated as the percentage increase above the control (EC_{50}) response to GABA in the presence of anesthetic (Koltchine et al., 1999).

Molecular volume calculation. Molecules were built in Spartan V5.1 (Wavefunction, San Diego, CA) and optimized with the Merck MMFF94 forcefield. The calculated volumes are van der Waals volumes and are given in Å³.

RESULTS

Different mutations are required to remove sensitivity to different anesthetics

The wild-type α2β1 GABA_α receptor is potentiated by isoflurane and halothane (Fig. 1a). The mutant receptor α2(S270H)β1 is insensitive to isoflurane (Krasowski et al., 1998) but shows normal sensitivity to the alkane anesthetic halothane (Fig. 1b). This finding initially suggested to us that S270 in TM2 might participate in binding isoflurane, but not halothane. The TM1 segment of the homologous glycine receptor was recently inferred to confer sensitivity to halothane (Greenblatt and Meng, 1999); we subsequently observed that the mutant GABA_α receptor α2(L232F)β1 was insensitive to halothane, whereas sensitivity to isoflurane remained (Fig. 1c). This finding suggested initially that L232 in TM1 might participate in binding halothane, but not isoflurane, and pointed to the possibility that these two anesthetics might act at different sites on the GABA_α receptor. However, when a larger Trp residue was introduced at S270, the mutant receptor α2(S270W)β1 was shown to lack sensitivity to halothane, as well as isoflurane (Fig. 1d).

Interestingly, this receptor retained sensitivity to a third anesthetic, chloroform (Fig. 1e). Mutation at A291 in TM3 of the α subunit has previously been shown to abolish receptor regulation by isoflurane (Krasowski et al., 1998), and we therefore added a second Trp residue at this position to create the double mutant α2(S270W; A291W)β1 receptor. This receptor was completely insensitive to chloroform (Fig. 1e), isoflurane, and halothane, but retained sensitivity to propofol (data not shown), an anesthetic believed to exert its actions via a site on the β subunit (Sanna et al., 1995; Krasowski et al., 1998).

The idea that the three residues (L232, S270, and A291) could be mutated to selectively or completely remove anesthetic modulation was then tested further. The S270W mutation was sufficient to remove isoflurane and halothane sensitivity, whereas the L232F mutation was sufficient to block potentiation by halothane but not isoflurane; in light of these observations, we also mutated L232 to tryptophan. The α2(L232W)β1 receptor expressed at normal levels and, like the α2(S270W)β1 receptor, was insensitive to potentiation by both halothane (−1.5 ± 4.8%; n = 20 cells) and isoflurane (5.8 ± 4.6%; n = 20 cells).

Anesthetics of dissimilar size have different cutoffs

The isoflurane sensitivity of the GABA_α receptor appears to show a cutoff effect when the receptor is mutated to increase the size of the residue at α270 (Koltchine et al., 1999). Specifically, in the series of mutant receptors α2(S270X)β1, these receptors become insensitive to isoflurane (molecular volume 144 Å³; Fig. 2a), because the volume of the side-chain is increased beyond the volume of threonine, i.e., after a change in volume δV > 30 Å³ (Fig. 2a). We repeated this analysis with the physically smaller anesthetics halothane (molecular volume 110 Å³) and chloroform (molecular volume 90 Å³), and in each case, a cutoff phenomenon was again observed. However, the cutoff occurred at larger side chain volumes than for isoflurane. For halothane this occurs between δV = 100–140 Å³ (Fig. 2b), whereas for chloroform the cutoff occurs between δV = 240–280 Å³ (Fig. 2c).

DISCUSSION

Multiple cutoffs suggest a common interaction site for three general anesthetics

We explain these experimental data by proposing that the side-chains at the key positions L232, S270, and A291 (in transmem-
brane segments TM1, TM2, and TM3, respectively, of the α subunit) define a binding cavity for small anesthetic molecules. Given our knowledge of the molecular volumes of the anesthetics and the cutoff data from our experiments, the volume of this hypothetical cavity can be estimated as between 250 and 370 Å³. The introduction by mutagenesis of bulky side chains at the critical sites presumably decreases the molecular volume of the anesthetics that can be accommodated within such a cavity. It should be noted that these cutoff effects are independent of anesthetic concentration (Koltchine et al., 1999).

The present results highlight the importance of the TM domains for receptor activation and regulation; mutating selected residues in the TM1 (Thompson et al., 1999), TM2 (Koltchine et al., 1999), and TM3 (Krasowski and Harrison, 2000) domains often results in changes in GABA EC₅₀. These mutations also affect the sensitivity of the receptor to a variety of allosteric modulators. For example, in addition to the changes in anesthetic sensitivity reported here, a mutation in TM1 α₁(T230I) renders α₁β3γ2s receptors more sensitive to the α6-specific noncompetitive antagonist furosemide; a similar result can be achieved by mutating (N265) in the β3 subunit (Thompson et al., 1999).

Three additional features of the experimental data are noteworthy. First, the data for the L232F and S270H mutants suggest that the anesthetics do not fit into the putative binding cavity in an identical manner; isoflurane (unlike halothane) is active at the L232F mutant receptor, whereas halothane (unlike isoflurane) is active at the S270H mutant. This could be explained if halothane makes a closer contact with L232 than does isoflurane, which may instead lie closer to S270, accounting for the very sharp cutoff in Figure 2a. The loss of sensitivity to both isoflurane and halothane after additional volume is added in the L232W or S270W mutants supports this idea and suggests that these two residues are part of the same cavity. Second, whereas the ability of isoflurane to enhance GABA currents falls off drastically as side-chain volume is increased at the 270 position, from serine to phenylalanine, halothane actually increases in effectiveness as the residue at 270 is expanded, before reaching the cutoff point at tryptophan. It is possible that for halothane (unlike isoflurane), the binding interactions with TM2 may be suboptimal in the wild-type receptor and are actually improved by the addition of a bulky side chain at 270. Finally, there is a marked discontinuity in the data for chloroform, at −ΔV = 40 Å³. One explanation for this observation would be a change from a cavity occupied by two chloroform molecules in the Asn mutant to a singly occupied cavity in the Glu mutant. If a cavity of >250 Å³ does exist within the wild-type α subunit, it should be possible for two molecules of chloroform (90 Å³) to bind simultaneously within such a cavity. There are existing precedents for double occupancy of cavities by general anesthetic molecules; for example, two molecules of halothane arranged in a head-to-head orientation are found within one of the anesthetic binding sites in human serum albumin (HSA) (Bhattacharya et al., 2000).

Small cavities bind general anesthetic molecules

Small cavities have been demonstrated to exist in a variety of globular proteins, both natural (Tilton et al., 1984; Eriksson et al., 1992; Kono et al., 2000) and synthetic (Johansson et al., 2000) in origin, and these can be altered in size and shape by mutagenesis of appropriate residues (Eriksson et al., 1992; Brunori et al., 2000; Kono et al., 2000; Lee et al., 2000). Anesthetics and other small gas molecules have been demonstrated to occupy such cavities, using a variety of techniques (Tilton et al., 1984; Franks et al., 1998; Brunori et al., 2000; Johansson et al., 2000). The binding of the anesthetic bromoform within a cavity in the enzyme firefly luciferase has been demonstrated using x-ray crystallography (Franks et al., 1998). Binding of such small ligands to protein cavities is often accompanied by the displacement of bound water molecules (Rashin et al., 1986; Matthews et al., 1995), and the interactions are further stabilized by low-energy (≤2–4 kcal/mol) van der Waals interactions with the cavity surface. The resulting free energy changes, although small, are commensurate with the relatively small energy changes associated with the gating of ligand-gated ion channels and are consistent with the low potentials for the anesthetic agents studied here (10⁻⁴–10⁻³ M). More recently, Bhattacharya et al. (2000) have obtained the high-resolution (2.4 Å) structure of halothane bound to HSA. In all of these cases, anesthetic binding produced no change in local or global protein structure. Instead, the halothane molecules simply occupied pre-existing cavities and made contacts with small polar and apolar amino acids forming the cavity walls.

An anesthetic binding cavity of defined volume in the GABAₐ receptor

The existence of a similar cavity or “crevice” within the GABAₐ receptor is supported by data from scanning cysteine accessibility mutagenesis experiments on TM3 in the α subunit (Williams and
Akabas, 1999). Moreover, recent experiments using cytochrome p450 substitutions in the transmembrane domain of the α subunit also indicate that Ser270 is likely to be involved in binding molecules such as ethanol and isoflurane. Mascia et al. (2000) showed that in the α2(S270C) mutant, an alkanethiol anesthetic and the sulfhydryl reagent propyl methanethiosulfonate produced an irreversible enhancement of receptor function. Furthermore, once alkylated, the α2(S270C) mutant was insensitive to isoflurane. These data suggest that α2(S270) is indeed involved in the binding of these anesthetic molecules.

The cutoff data reported here predict that the receptor should be modulated by molecules larger than isoflurane. This is indeed the case; halogenated ether anesthetics (sevoflurane; 154 Å3) and long-chain alcohols (decanol; 234 Å3) both potentiate GABA<sub>A</sub> receptor function (Dildy-Mayfield et al., 1996; Krasowski and Harrison, 2000). Interestingly, Ser270 is also critical for the action of alcohols (Mihic et al., 1997; Mascia et al., 2000) and so it is important to note that the cutoffs for the actions of the n-alkanols on the GABA<sub>A</sub> receptor occur between decanol and dodecanol, i.e., somewhere between 234 and 276 Å3 (Dildy-Mayfield et al., 1996); at mutations the homologous I307 residue in human GABA<sub>A</sub> or the S267 residue in human GlyR α1 alter alcohol cutoff in these related receptors (Wick et al., 1998).

In conclusion, we suggest that modulation of GABA<sub>A</sub> receptor function by small general anesthetic molecules results from occupation of a cavity of volume ~250–370 Å3, the surface of which is partly defined by L232, S270, and A291. It is therefore of considerable interest that cutoff data from in vivo experiments also point to a maximal volume for anesthetic activity of ~340 Å3 (Curry et al., 1991).

REFERENCES


GABA<sub>A</sub> receptor determined by the volume of a TM2 residue. Mol Pharmacol 56:1087–1093.


